William Blair analyst Myles Minter has maintained their bullish stance on ALNY stock, giving a Buy rating yesterday.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Myles Minter has given his Buy rating due to a combination of factors including Alnylam Pharma’s impressive financial performance and strategic advancements. The company’s quarterly revenues significantly exceeded expectations, with a notable performance from the TTR franchise, particularly the Amvuttra launch in ATTR-cardiomyopathy, which outperformed projections and contributed to a substantial increase in revenue guidance.
Additionally, Alnylam’s narrower-than-expected GAAP net loss and the substantial increase in their revenue guidance for 2025 further support the positive outlook. The company’s ability to raise its total net product revenue guidance by 27% and maintain its expectations for profitability based on non-GAAP operating income underscores its strong market position and growth potential, making it a compelling investment opportunity.
In another report released yesterday, Bernstein also maintained a Buy rating on the stock with a $389.00 price target.